|
|
Blood, 1 August 2004, Vol. 104, No. 3, pp. 744-751.
Prepublished online as a Blood First Edition Paper on March 4, 2004; DOI 10.1182/blood-2003-11-3762.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
CD40 activation of BCP-ALL cells generates IL-10–producing, IL-12–defective APCs that induce allogeneic T-cell anergy
Giovanna D'Amico,
Marisa Vulcano,
Cristina Bugarin,
Giancarlo Bianchi,
Gisella Pirovano,
Martin Bonamino,
Virna Marin,
Paola Allavena,
Ettore Biagi, and
Andrea Biondi
From the Centro Ricerca M. Tettamanti, Clinica Pediatrica Università Milano-Bicocca, Ospedale San Gerardo, Monza, Italy; and the Department of Immunology, Istituto "Mario Negri," Milan, Italy.
The use of leukemia cells as antigen-presenting cells (APCs) in immunotherapy is critically dependent on their capacity to initiate and sustain an antitumor-specific immune response. Previous studies suggested that pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells could be manipulated in vitro through the CD40-CD40L pathway to increase their immunostimulatory capacity. We extended the APC characterization of CD40L-activated BCP-ALL for their potential use in immunotherapy in a series of 19 patients. Engaging CD40 induced the up-regulation of CCR7 in 7 of 11 patients and then the migration to CCL19 in 2 of 5 patients. As accessory cells, CD40L-activated BCP-ALL induced a strong proliferation response of naive T lymphocytes. Leukemia cells, however, were unable to sustain proliferation over time, and T cells eventually became anergic. After CD40-activation, BCP-ALL cells released substantial amounts of interleukin-10 (IL-10) but were unable to produce bioactive IL-12 or to polarize TH1 effectors. Interestingly, adding exogenous IL-12 induced the generation of interferon- (IFN-)–secreting TH1 effectors and reverted the anergic profile in a secondary response. Therefore, engaging CD40 on BCP-ALL cells is insufficient for the acquisition of full functional properties of immunostimulatory APCs. These results suggest caution against the potential use of CD40L-activated BCP-ALL cells as agents for immunotherapy unless additional stimuli, such as IL-12, are provided.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Glouchkova, B. Ackermann, A. Zibert, R. Meisel, M. Siepermann, G. E. Janka-Schaub, U. Goebel, A. Troeger, and D. Dilloo
The CD70/CD27 Pathway Is Critical for Stimulation of an Effective Cytotoxic T Cell Response against B Cell Precursor Acute Lymphoblastic Leukemia
J. Immunol.,
January 1, 2009;
182(1):
718 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Fujii, J. D. Trudeau, D. T. Teachey, J. D. Fish, S. A. Grupp, K. R. Schultz, and G. S. D. Reid
In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides
Blood,
March 1, 2007;
109(5):
2008 - 2013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Inoue, W. W. Leitner, B. Golding, and D. Scott
Inhibitory effects of B cells on antitumor immunity.
Cancer Res.,
August 1, 2006;
66(15):
7741 - 7747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. D. Reid, K. She, L. Terrett, M. R. Food, J. D. Trudeau, and K. R. Schultz
CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response
Blood,
May 1, 2005;
105(9):
3641 - 3647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. N. Cooper, Z. Al-Kadhimi, L. M. Serrano, T. Pfeiffer, S. Olivares, A. Castro, W.-C. Chang, S. Gonzalez, D. Smith, S. J. Forman, et al.
Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1
Blood,
February 15, 2005;
105(4):
1622 - 1631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
